Truist Financial Corp Grows Position in Johnson & Johnson (NYSE:JNJ)

Truist Financial Corp grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 0.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,586,357 shares of the company's stock after acquiring an additional 4,097 shares during the quarter. Truist Financial Corp owned about 0.07% of Johnson & Johnson worth $263,082,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Eukles Asset Management increased its holdings in Johnson & Johnson by 0.8% in the 1st quarter. Eukles Asset Management now owns 11,155 shares of the company's stock worth $1,850,000 after buying an additional 89 shares in the last quarter. Capital Investment Advisory Services LLC grew its stake in shares of Johnson & Johnson by 1.6% during the 1st quarter. Capital Investment Advisory Services LLC now owns 31,394 shares of the company's stock valued at $5,206,000 after purchasing an additional 488 shares during the period. Element Wealth LLC grew its stake in shares of Johnson & Johnson by 5.8% during the 1st quarter. Element Wealth LLC now owns 1,886 shares of the company's stock valued at $313,000 after purchasing an additional 104 shares during the period. Argyle Capital Management LLC grew its stake in shares of Johnson & Johnson by 0.8% during the 1st quarter. Argyle Capital Management LLC now owns 26,004 shares of the company's stock valued at $4,313,000 after purchasing an additional 200 shares during the period. Finally, Brookstone Capital Management grew its stake in shares of Johnson & Johnson by 1.7% during the 1st quarter. Brookstone Capital Management now owns 73,544 shares of the company's stock valued at $12,197,000 after acquiring an additional 1,199 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on JNJ. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Royal Bank Of Canada restated an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 5th. Barclays dropped their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Morgan Stanley upped their price target on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Stock Down 0.5%

JNJ stock traded down $0.78 during mid-day trading on Monday, reaching $155.23. The company had a trading volume of 6,263,851 shares, compared to its average volume of 8,052,571. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a market capitalization of $373.49 billion, a price-to-earnings ratio of 17.27, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41. The firm has a fifty day simple moving average of $153.68 and a 200 day simple moving average of $154.17.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. Analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.35%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.